Read more
1:32 PM ยท 21 June 2024

Sarepta Therapeutics gains 37% in pre-market after FDA approval ๐Ÿ“ƒ

Sarepta Therapeutics' soared by 36% in the pre-market trading following the FDA's decision to grant accelerated approval for its gene therapy, Elevidys, extending its use to include non-ambulatory patients with Duchenne muscular dystrophy (DMD). Additionally, the FDA granted traditional approval for Elevidys to treat ambulatory DMD patients who are at least four years old. This broader approval aims to increase access to Elevidys, which costs around $3.2 million per patient, positioning it as one of the most expensive drugs globally. Sarepta has commenced the ENVISION study, a phase 3 trial, to confirm Elevidys' benefits in non-ambulatory and older ambulatory patients, a requirement for maintaining its FDA approval for these groups.

The FDA's decision marks a significant expansion in the treatment of DMD, a serious muscle-weakening disease that mainly affects men in their 20s. Yesterday's FDA approval offers a potential opportunity to significantly increase the company's revenues. Sarepta's strategy includes partnering with Roche Holdings for global commercialization, excluding the US, where Sarepta will remain fully responsible for commercialization.

Source: xStation 5

30 April 2026, 3:41 PM

๐Ÿ—ฝS&P 500 companies with the record net margin since 2009 - FactSet data

30 April 2026, 2:04 PM

Market Wrap: UK100 skyrockets after BoE ๐Ÿ‡ฌ๐Ÿ‡ง ๐Ÿš€ Euphoric gain as ECB Lagarde speaks ๐Ÿ‡ช๐Ÿ‡บ ๐Ÿ“ˆ

30 April 2026, 1:34 PM

Apple Q2 2026: stable results or the beginning of a new growth cycle?

30 April 2026, 6:55 AM

Morning Wrap: Record-breaking Big Tech results driven by AI, Fed delivers no surprises

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissรฃo de Valores Mobiliรกrios (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits